DK0814787T3 - Olie-i-vand emulsioner indeholdende propofol og dinatrium-edetat - Google Patents

Olie-i-vand emulsioner indeholdende propofol og dinatrium-edetat

Info

Publication number
DK0814787T3
DK0814787T3 DK95911412T DK95911412T DK0814787T3 DK 0814787 T3 DK0814787 T3 DK 0814787T3 DK 95911412 T DK95911412 T DK 95911412T DK 95911412 T DK95911412 T DK 95911412T DK 0814787 T3 DK0814787 T3 DK 0814787T3
Authority
DK
Denmark
Prior art keywords
oil
water emulsions
disodium edetate
water
emulsions containing
Prior art date
Application number
DK95911412T
Other languages
Danish (da)
English (en)
Inventor
Christopher Buchan Jones
John Henry Platt
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48793621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0814787(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK0814787T3 publication Critical patent/DK0814787T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DK95911412T 1994-03-22 1995-03-17 Olie-i-vand emulsioner indeholdende propofol og dinatrium-edetat DK0814787T3 (da)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
GB9405593A GB9405593D0 (en) 1994-03-22 1994-03-22 Pharmaceutical compositions
CA002212794A CA2212794C (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate
PL95322278A PL186354B1 (pl) 1994-03-22 1995-03-17 Jałowe kompozycje farmaceutyczne oraz sposoby ograniczania potencjału wzrostowego drobnoustrojów i poprawiania czasu stosowania emulsji
EP95911412A EP0814787B1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and disodium edetate
NZ282005A NZ282005A (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol (2,6 diisopropylphenol) and edetate
NZ500588A NZ500588A (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate for producing anaesthesia
ZA952239A ZA952239B (en) 1994-03-22 1995-03-17 Pharmaceutical compositions
BE9500241A BE1009198A5 (fr) 1994-03-22 1995-03-17 Compositions pharmaceutiques nouvelles contenant du propofol.
FR9503128A FR2731617B1 (fr) 1994-03-22 1995-03-17 Compositions pharmaceutiques nouvelles contenant du propofol
CH02011/97A CH693764A5 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzung enthaltend Propofol und Edetat.
CH00393/03A CH693762A5 (de) 1994-03-22 1995-03-17 Wässrige Zusammensetzungen enthaltend eine Öl-in-Wasser-Emulsion
BR9510452A BR9510452A (pt) 1994-03-22 1995-03-17 Composição farmacêutica e aquosa estéril para a administração parenteral processos para limitar o potencial de crescimento microbiano em composição farmacêutica estéril para a administração parenteral para produzir anestesia em um animal de sangue quente e para aperfeiçoar o tempo de administração e/ou o tempo entre as trocas de conjuntos
DE19509828A DE19509828A1 (de) 1994-03-22 1995-03-17 Pharmazeutische Zusammensetzungen
PCT/GB1995/000579 WO1996029064A1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and edetate
HU9702180A HU227951B1 (en) 1994-03-22 1995-03-17 Oil in water emulsions containing propofol and disodium edetate
CH01282/04A CH694423A5 (de) 1994-03-22 1995-03-17 Verwendung von Edetat zur Stabilisierung von pharmzeutischen Zusammensetzungen.
NO19974278A NO320007B1 (no) 1994-03-22 1997-09-16 Steril farmasoytisk blanding inneholdende propofol og edetat for parenteral administrering, fremgangsmate for a begrense potensialet for mikrobevekst i blandingen, samt anvendelse derav.
JP00624199A JP4012328B2 (ja) 1994-03-22 1999-01-13 エデテートを含有する水中油滴エマルジョン
FI20085586A FI120641B (fi) 1994-03-22 2008-06-13 Ruuansulatuskanavan ulkopuolisesti annettavat rasvaemulsiot, jotka sisältävät edetaattia säilöntäaineena

Publications (1)

Publication Number Publication Date
DK0814787T3 true DK0814787T3 (da) 2003-01-06

Family

ID=48793621

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02009330T DK1238677T3 (da) 1994-03-22 1995-03-17 Parenterale fedtemulsioner, der omfatter edetat som konserveringsmiddel
DK95911412T DK0814787T3 (da) 1994-03-22 1995-03-17 Olie-i-vand emulsioner indeholdende propofol og dinatrium-edetat
DK106697A DK106697A (da) 1994-03-22 1997-09-17 Emulsioner af typen olie-i-vand indeholdende propofol og edetat

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02009330T DK1238677T3 (da) 1994-03-22 1995-03-17 Parenterale fedtemulsioner, der omfatter edetat som konserveringsmiddel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK106697A DK106697A (da) 1994-03-22 1997-09-17 Emulsioner af typen olie-i-vand indeholdende propofol og edetat

Country Status (33)

Country Link
US (1) US5714520A (it)
EP (2) EP0814787B1 (it)
JP (2) JP3067806B2 (it)
AT (2) ATE226817T1 (it)
AU (1) AU710143B2 (it)
BE (1) BE1009198A5 (it)
BR (1) BR9510452A (it)
CA (1) CA2212794C (it)
CH (4) CH694423A5 (it)
CZ (1) CZ297549B6 (it)
DE (2) DE19509828A1 (it)
DK (3) DK1238677T3 (it)
ES (2) ES2253469T3 (it)
FI (2) FI120640B (it)
FR (1) FR2731617B1 (it)
GB (2) GB9405593D0 (it)
HK (1) HK1008927A1 (it)
HU (1) HU227951B1 (it)
IL (1) IL113021A (it)
IT (1) IT1281193B1 (it)
LU (1) LU90136B1 (it)
MX (1) MX9707005A (it)
NO (2) NO320007B1 (it)
NZ (2) NZ282005A (it)
PL (1) PL186354B1 (it)
PT (1) PT814787E (it)
RU (1) RU2147432C1 (it)
SE (2) SE523909C2 (it)
SI (1) SI0814787T1 (it)
SK (1) SK286375B6 (it)
TW (1) TW458781B (it)
WO (1) WO1996029064A1 (it)
ZA (1) ZA952239B (it)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
MY113046A (en) * 1994-03-22 2001-11-30 Astrazeneca Uk Ltd Pharmaceutical compositions
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US20020173547A1 (en) 1994-03-22 2002-11-21 Jones Christopher Buchan Pharmaceuticals compositions
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
KR19980025601A (ko) * 1996-10-04 1998-07-15 우동일 혈관주사제용 프로포폴 유탁액의 제조방법
CH692322A5 (it) 1997-05-26 2002-05-15 Westy Ag Formulazione iniettabile limpida di Propofol.
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DE19757224A1 (de) 1997-12-22 1999-07-01 Bayer Ag Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation
AU750040B2 (en) * 1998-02-10 2002-07-11 Sicor Inc. Propofol composition containing sulfite
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
IL141095A0 (en) * 1998-08-19 2002-02-10 Rtp Pharma Inc Injectable aqueous dispersions of propofol
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6140373A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
PT1143962E (pt) * 1999-01-28 2005-03-31 Kurani Shashikant Prabhudas Solucao parenterica de propofol (2,6-di-isopropilfenol) e 2,5-di-o-metil-1,4;3,6-di-anidro-d-glucitol, como dissolvente
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
CN1149984C (zh) * 1999-06-21 2004-05-19 健一制药株式会社 用于静脉注射的含有普鲁泊福的麻醉组合物
GB2359747B (en) 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
EP1289518A2 (en) * 2000-05-25 2003-03-12 AstraZeneca AB Pharmaceutical composition comprising a free-radical scavenging sedative agent and a metal ion chelating agent
JP2003535884A (ja) * 2000-06-16 2003-12-02 スカイファーマ・カナダ・インコーポレーテッド プロポフォールの改善された注射可能な分散物
IN188917B (it) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
WO2002092082A1 (en) 2001-05-11 2002-11-21 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
JP4127757B2 (ja) * 2001-08-21 2008-07-30 株式会社エヌ・ティ・ティ・ドコモ 無線通信システム、通信端末装置、及びバースト信号送信方法
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US8541472B2 (en) 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
PL207038B1 (pl) 2002-01-25 2010-10-29 Theravance Podstawione pochodne kwasu fenylooctowego, związek pośredni, kompozycja farmaceutyczna zawierająca te pochodne oraz ich zastosowanie
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
ATE343376T1 (de) * 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
MXPA04009703A (es) * 2002-04-08 2004-12-13 Guilford Pharm Inc Composiciones farmaceuticas que contienen promedicamentos solubles en agua de propofol y metodoss para administrar los mismos.
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
CN100438861C (zh) 2002-07-29 2008-12-03 变换药品公司 含水2,6-二异丙基苯酚药物组合物
CA2503956A1 (en) * 2002-10-29 2004-05-13 Transform Pharmaceuticals, Inc. Propofol with cysteine
AU2003299590B8 (en) * 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
DK1648413T3 (da) * 2003-07-23 2010-01-11 Theravance Inc Farmaceutiske præparater af kortvirkende sedativt sövndyssende middel
US8546453B2 (en) * 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
CN1882548A (zh) * 2003-10-24 2006-12-20 奥斯佩克斯制药公司 2,6－二异丙基苯酚的pH敏感性前药
CN100479812C (zh) 2004-02-13 2009-04-22 生物药效率有限公司 麻醉用高浓度异丙酚微乳制剂
EA200700440A1 (ru) * 2004-09-13 2008-02-28 Бхарат Сирумс Энд Вэксинс Лтд. Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
EP1850829A4 (en) * 2005-02-03 2012-12-26 Taro Pharmaceuticals Usa Inc NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS
WO2006089120A2 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Inc Compositions, methods of use and preparation of 2,6-diisopropyl phenol and analogs for ischemic injury
US20090131538A1 (en) * 2005-05-27 2009-05-21 Taro Pharmaceuticals North America, Inc. c/o Taro Pharmaceuticals U.S.A., Inc. Novel propofol composition comprising a pharmaceutically acceptable salt of formaldehyde sulfoxylate
WO2007052288A2 (en) * 2005-08-05 2007-05-10 Bharat Serums & Vaccines Ltd. Intravenous propofol emulsion compositions having preservative efficacy
KR20080055804A (ko) * 2005-08-12 2008-06-19 바라트 쎄럼스 앤드 백신스 리미티드 프로포폴을 포함하는 수성 마취 조성물
US20080234229A1 (en) * 2005-08-18 2008-09-25 Auspex Pharmaceuticals, Inc. Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
TR200801336T1 (tr) 2005-08-31 2008-08-21 Abraxis Bioscience, Inc. Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
US7589239B2 (en) * 2005-09-02 2009-09-15 Auspex Pharmaceuticals Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
CN1903187B (zh) * 2006-03-21 2012-05-30 沈阳药科大学 含有局麻药的复方异丙酚注射剂及制备工艺
MX2009012125A (es) * 2007-05-09 2010-02-18 Pharmacofore Inc Compuestos terapeuticos.
CN101715437B (zh) * 2007-05-09 2013-06-12 特色疗法股份有限公司 立体异构异丙酚治疗性化合物
KR20080102010A (ko) * 2007-05-17 2008-11-24 대원제약주식회사 프로포폴을 포함하는 주사제용 조성물 및 이의 제조 방법
WO2010014727A1 (en) 2008-08-01 2010-02-04 The Medicines Company Pharmaceutical compositions and methods for producing low impurity concentrations of the same
US9132090B2 (en) 2009-01-13 2015-09-15 Chetan Majmudar Propofol based anesthetic with preservative
JP6040437B2 (ja) * 2010-10-12 2016-12-07 チエシイ ファルマセウティシ ソシエタ ペル アチオニＣｈｉｅｓｉ Ｆａｒｍａｃｅｕｔｉｃｉ Ｓ．Ｐ．Ａ． 抗菌剤を含むクレビジピン乳化製剤
US8658676B2 (en) 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN102407986B (zh) * 2011-11-03 2013-11-27 南通四方冷链装备股份有限公司 隔料装置
CN102525921B (zh) 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
CN102579555A (zh) * 2012-03-01 2012-07-18 四川大学华西医院 注射用脂肪乳在作为拮抗全身麻醉用药作用的药物制备中的应用
IN2014DN10322A (it) 2012-05-16 2015-08-07 Mewa Singh
WO2017031261A1 (en) 2015-08-20 2017-02-23 Mewa Singh Polyphenolic polymer to make water-insoluble molecules become water-soluble
EP3612229A4 (en) 2017-04-19 2020-04-29 Mayo Foundation for Medical Education and Research KETAMINE AND PROPOLE ADDITIVE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3384545A (en) * 1965-03-09 1968-05-21 Hoffmann La Roche Injectable aqueous emulsions of fat soluble vitamins
US3230143A (en) * 1965-05-14 1966-01-18 Merck & Co Inc Antihypertensive injection methods using acid addition salts of alkyl esters of alpha-methyl-3, 4-dihy-droxyphenylalanine
DE1792410B2 (de) * 1967-09-01 1980-03-13 Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm Arzneimittelzubereitung zur intravenösen Injektion
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4328213A (en) * 1979-11-28 1982-05-04 Schering Corporation Stable injectable labetalol formulation
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
JPS5916818A (ja) * 1982-07-20 1984-01-28 Shimizu Seiyaku Kk 経静脈投与用輸液剤
SE8505047L (sv) * 1985-10-25 1987-04-26 Nutritional Int Res Inst Fettemulsion
IL83086A (en) * 1987-07-06 1991-03-10 Teva Pharma Stable,injectable solutions of vincristine salts
US4868169A (en) * 1987-11-13 1989-09-19 E. R. Squibb & Sons, Inc. Steroid cream formulation
JPH075456B2 (ja) * 1988-10-01 1995-01-25 参天製薬株式会社 点眼液
JPH03503171A (ja) * 1988-11-29 1991-07-18 ユニリーバー・ナームローゼ・ベンノートシヤープ 抗菌薬及びその使用
GB8828517D0 (en) * 1988-12-07 1989-01-11 Leopold & Co Ag Stable emulsions
US5079003A (en) * 1990-03-14 1992-01-07 Adelia Scaffidi Skin lotions and creams
JP3308555B2 (ja) * 1991-03-08 2002-07-29 カネボウ株式会社 微細化エマルション組成物の製造方法
JP2811036B2 (ja) * 1992-05-26 1998-10-15 参天製薬株式会社 ビタミンｅ点眼剤
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
CH693762A5 (de) 2004-01-30
EP0814787B1 (en) 2002-10-30
JP4012328B2 (ja) 2007-11-21
EP1238677A3 (en) 2003-01-22
FI20085586A (fi) 2008-06-13
IT1281193B1 (it) 1998-02-17
DK1238677T3 (da) 2006-03-06
HK1008927A1 (en) 1999-07-16
HUT77358A (hu) 1998-03-30
ES2183869T3 (es) 2003-04-01
SE523909C2 (sv) 2004-06-01
AU710143B2 (en) 1999-09-16
FI973702A0 (fi) 1997-09-16
SE9703274D0 (sv) 1997-09-10
ITMI950529A1 (it) 1996-09-17
CA2212794A1 (en) 1996-09-26
NZ282005A (en) 2000-01-28
JP3067806B2 (ja) 2000-07-24
AU1898895A (en) 1996-10-08
JPH11263725A (ja) 1999-09-28
NZ500588A (en) 2001-04-27
BR9510452A (pt) 1998-05-19
EP1238677A2 (en) 2002-09-11
GB2298789A (en) 1996-09-18
SE527123C2 (sv) 2005-12-27
EP0814787A1 (en) 1998-01-07
DK106697A (da) 1997-09-17
IL113021A0 (en) 1995-12-08
NO974278D0 (no) 1997-09-16
FI120641B (fi) 2010-01-15
FR2731617A1 (fr) 1996-09-20
NO320007B1 (no) 2005-10-10
ATE226817T1 (de) 2002-11-15
CZ290497A3 (en) 1997-12-17
DE69528714D1 (de) 2002-12-05
SE0400115L (sv) 2004-01-21
GB9505405D0 (en) 1995-05-03
ES2253469T3 (es) 2006-06-01
CA2212794C (en) 2000-09-12
CZ297549B6 (cs) 2007-02-07
DE19509828A1 (de) 1996-09-19
CH693764A5 (de) 2004-01-30
NO974278L (no) 1997-09-16
SK124797A3 (en) 1998-01-14
SE9703274L (sv) 1997-09-10
SE0400115D0 (sv) 2004-01-21
FI120640B (fi) 2010-01-15
CH694423A5 (de) 2005-01-14
LU90136B1 (de) 1997-11-27
DE69528714T2 (de) 2003-06-12
US5714520A (en) 1998-02-03
ATE312625T1 (de) 2005-12-15
FI973702A (fi) 1997-09-16
ZA952239B (en) 1996-09-17
NO334956B1 (no) 2014-08-04
BE1009198A5 (fr) 1996-12-03
CH694396A5 (de) 2004-12-31
FR2731617B1 (fr) 1997-05-30
IL113021A (en) 2001-04-30
SI0814787T1 (en) 2003-04-30
PL186354B1 (pl) 2003-12-31
EP1238677B1 (en) 2005-12-14
WO1996029064A1 (en) 1996-09-26
TW458781B (en) 2001-10-11
GB2298789B (en) 1999-12-08
PL322278A1 (en) 1998-01-19
HU227951B1 (en) 2012-07-30
ITMI950529A0 (it) 1995-03-17
RU2147432C1 (ru) 2000-04-20
PT814787E (pt) 2003-02-28
GB9405593D0 (en) 1994-05-11
JPH11500737A (ja) 1999-01-19
SK286375B6 (sk) 2008-08-05
NO20041838L (no) 1997-09-16
MX9707005A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
DK0814787T3 (da) Olie-i-vand emulsioner indeholdende propofol og dinatrium-edetat
IL114212A (en) Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE69016749T2 (de) Emulsion.
DE69625213T2 (de) Mikroemulsionen zur verwendung als träger zur verabreichung von wirkstoffen
KR870002835A (ko) 이온화성 소수성약제의 약제학적 제조방법
DE69011922T2 (de) Arzneiemulsionen.
IS4224A (is) Lyfjablanda á formi dropalausnar sem inniheldur skammvirkt kalsíummótlyf af tvíhýdrópýridíngerð semvinna gegn háþrýstingi
NO961363D0 (no) Nytt emulsjonspreparat
BR0111136A (pt) Composição farmacêutica estéril, uso da mesma, e, método para melhorar a sobrevivência de um paciente doente em estado crìtico
DE60029948D1 (de) Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut
SE8705064D0 (sv) Emulsion for parenteral administrering
TH44063A (th) วิธีป้องกันการอาเจียนและการรักษาการเสื่อมสมรรถภาพทางเพศโดยใช้เททระไฮโรเบนซ์(cd) อินโคล-6- คาร์บอกแซมีด